Navigation Links
Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
Date:2/11/2008

FREDERICK, Md., Feb. 11 /PRNewswire/ -- Cancer research pioneer Michael G. Hanna Jr. Ph.D., also Vaccinogen, Inc.'s Founder, Chairman and CEO has acquired the rights to OncoVAX(R), a vaccine with the potential to prevent colon cancer from recurring in many patients.

"This agreement represents a major step forward in defeating cancer by increasing the body's immunity to it," said Dr. Hanna, who has been working on cancer vaccines for more than 30 years.

In the agreement, Vaccinogen obtained exclusive license to OncoVAX(R) Active Specific Immunotherapy as well as an important component of the product TICE BCG. The vaccine is made from the patients' own tumor and is injected back into the patient to effect an immune response against recurrence of that cancer.

The FDA views Stage II colon cancer as an unmet medical need. When colon cancer recurs after surgery it is frequently fatal. OncoVAX(R) prevents that recurrence and thereby reduces recurrence and deaths by over 50%. Vaccinogen is currently preparing to commercialize the vaccine in Switzerland.

About OncoVAX(R)

OncoVAX(R) immunotherapy is based on a decades-long attempt by scientists to transform the body's immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases. Immune stimulation should be able to create a population of white blood cells that can kill tumor cells wherever they arise in the body, years after surgical removal of the original tumor.

Vaccinogen's scientists prepare a vaccine from the patient's own tumor. The cells are dissociated, irradiated to make them non-tumorigenic and administered to the patient by three weekly injections, starting four weeks after surgery. A booster vaccination is administered six months later.

About Vaccinogen

Vaccinogen is a biopharmaceutical company developing and commercializing canc
'/>"/>

SOURCE Vaccinogen
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2008)...nted at the 27th Annual Meeting of the American Pa... SMYRNA, Ga., May 8 /- Patients treat...ief from diabetic neuropathic pain (DNP),compared...esented at the,27th annual meeting of the American...first placebo-controlled trial of a diabetic neuro...
(Date:5/8/2008)...loan-Kettering Cancer Center Investigators to Asse...ian Cancer Patients -, BRISBANE, Calif., May 8 /P... the expansion of Phase 2 clinical trial programs ...This is the third major clinical trial,of BSI-201 ...nding on,on-going trials in breast and brain cance...
(Date:5/8/2008)...ation May Provide New Option for Clinicians Concer...ng an Oral NSAID, TAMPA, Fla., May 8 /PRNewswire-...ng global specialty pharmaceutical company, announ...ek at the American Pain Society annual,meeting dem...harmacokinetic,profile of Alpharma Pharmaceuticals...
(Date:5/7/2008)... Study to Evaluate Efficacy and Safety in Treating...dness, LEVERKUSEN, Germany, MONTVILLE, New Jersey...all/ -- Bayer HealthCare AG and Regeneron,Pharmace...t the first patient,has been dosed in the VIEW 2 t...ment program evaluating VEGF Trap-Eye for the trea...
Breaking Medicine Technology:New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 2Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 3Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 4Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 5Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration 6NOLabs AB Achieves Break Through in Fight Against MRSA Bacteria 2017 1NOLabs AB Achieves Break Through in Fight Against MRSA Bacteria 2017 2Cord Blood America Announces Financing 2015 1Cord Blood America Announces Financing 2015 2Cord Blood America Announces Financing 2015 3Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline 7266 1Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline 7266 2Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline 7266 3Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline 7266 4Cell Therapeutics Inc Announces 246 5 Million Offering 7264 1Cell Therapeutics Inc Announces 246 5 Million Offering 7264 2Cell Therapeutics Inc Announces 246 5 Million Offering 7264 3
...hink, Inc. (NASDAQ:,ANSR) announced today that it ...ciences Group for the distribution of LORENZ solut... Sciences Group will,serve midsize companies by in...utions into Answerthink,s Life Science solutions,b...red EzLifeSciences solutions are,designed specific...
...or Obama today,released the following statement in...ll:, "By vetoing funding for stem cell research on...millions of Americans who do,not have the time to ...their lives. The promise that stem cells hold does...judgment of science, and we,deserve a President wh...
Other Medicine Technology:Answerthink and LORENZ Life Sciences Group Announce Strategic,Alliance for the SAP Life Science Industry 2Answerthink and LORENZ Life Sciences Group Announce Strategic,Alliance for the SAP Life Science Industry 3
(Date:5/10/2008)...to play smart to avoid devastating vision injuries...hDay News) -- Every year in the United States, abo...s, says the American Academy of Ophthalmology (AAO...iate, sports-specific eye protection properly fitt...rom polycarbonate materials offer the highest leve...
(Date:5/9/2008)...Calif., May 9 /PRNewswire-USNewsire/ -- U.S.,corpo...to help victims of,the Cyclone Nargis in Myanmar a...lief International, to ensure that the aid will re..., "It,s important to remember the complete story ...rts with the people and organizations that,provide...
(Date:5/9/2008)... May 9 /PRNewswire-USNewswire/ -- Metaverse develo...lieve the unspeakable human,suffering in Myanmar i...sks,have been developed and are being placed in hi...d Life, with coordination being arranged via the,S...p://slurl.com/secondlife/Simuality/106/83/41 )., ...
(Date:5/9/2008)... stimulants a fixture of European nightlife, study... -- Many teens and young adults in Europe are drin... according to a survey of more than 1,300 people w...showed that a third of males and a quarter of fema...chances of sex, while cocaine, ecstasy and cannabi...
Breaking Medicine News(10 mins):Health News:Protective Eyewear Key to Sports Safety 2Health News:Direct Relief's Corporate Partners Key to Aiding Cyclone Victims 2Health News:Young Adults Using Alcohol, Drugs for Better Sex 2
... of anabolic androgenic steroid (AAS) is linked to...// Gingival enlargement occurs when the tissues s...ertile environment for bacteria to grow, which can...as found that AAS abusers had statistically signif...
...onference from 31st July to 5th August is expected... life//. Autism is a condition that reportedly af... more common than the combined conditions like chi...ltiple sclerosis combined. Living with an autistic...
...ospitals are repeatedly failing to implement rules...sed to patients //from contaminated surgical instr...ot keeping instruments in sets so they can be trac... being swapped for operations, they allege. Dr Gi...
...s found that food rich in carbohydrates was very e...to other diets. The study results are to be presen...and Technology Incorporated Convention in Adelaide...sity of Melbourne research dietician Liz Delbridge...
Other Medicine News:Health News:A connection between gingival enlargement and steroid abuse 2Health News:National Autism Conference In US Expected To Draw Thousands In Attendance 2
Compact networked patient monitors for flexible care.
... monitoring, IntelliVue has highly flexible screen... menu; built-in clinical support tools such as Eve...rhythmia analysis; and many other powerful feature...networked platform that can span the hospital ente...
...power of the Nightingale system is further magnifi...s to Zoe Medical's Online Care Unit™ (OCU). ... that serves as a secure, central clearinghouse fo...e Monitoring System that has been configured to ha...
Generra Narkotron II is a comprehensive vital sign monitor. , ,Adult, pediatric, and neonatal. , ,Providing high quality, affordable products for efficiency in patient care., ,Standard Functions:
Medicine Products: